CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

  • Current Quote
  • Stock Chart
$4.18 + 0.01 (0.24%)
Day High:$4.21
Day Low:$4.13
05/26/174:00 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345


Recent News

May 03, 2017CTI BioPharma Reports First Quarter 2017 Financial Results
- Pacritinib Marketing Authorization Application Submission Expected Mid-Year - Expanded Partnership with Servier for Commercialization of PIXUVRI® - Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern time SEATTLE, May 3, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the first quarter ended March 31, 2017. Recent Highlights In April 2017, CTI BioPharma announced the expansion of the existing license and ... 
Printer Friendly Version
Apr 26, 2017CTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017
SEATTLE, April 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows: ... 
Printer Friendly Version
Apr 25, 2017Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
- Servier will commercialize PIXUVRI in all markets except the US - CTI BioPharma will retain rights to commercialize PIXUVRI in the US PARIS and SEATTLE, April 25, 2017 /PRNewswire/ -- Servier and CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today jointly announced that they agreed to expand their existing license and development collaboration agreement for PIXUVRI® (pixantrone). Under this expanded agreement, Servier will have rights to PIXUVRI in all markets except the U... 
Printer Friendly Version


There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.